How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 1, Pages 155
Publisher
MDPI AG
Online
2022-12-28
DOI
10.3390/cancers15010155
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
- (2022) Meletios A. Dimopoulos et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience
- (2022) Meera Mohan et al. AMERICAN JOURNAL OF HEMATOLOGY
- Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
- (2022) Fredrik Schjesvold et al. HAEMATOLOGICA
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
- (2022) Thierry Facon et al. HEMATOLOGICAL ONCOLOGY
- LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
- (2022) Maria-Victoria Mateos et al. LEUKEMIA
- Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: Subgroup analyses from ICARIA-MM and IKEMA
- (2022) Tom Martin et al. HAEMATOLOGICA
- Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.
- (2022) Doris K. Hansen et al. JOURNAL OF CLINICAL ONCOLOGY
- Teclistamab in Relapsed or Refractory Multiple Myeloma
- (2022) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- UPDATED PROGRESSION-FREE SURVIVAL AND DEPTH OF RESPONSE IN IKEMA, A RANDOMIZED PHASE 3 TRIAL OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA
- (2022) M Capra et al. Hematology Transfusion and Cell Therapy
- Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
- (2022) Paul G. Richardson et al. BLOOD
- Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
- (2022) Paul G. Richardson et al. BLOOD
- Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis
- (2021) Leonardo Javier Arcuri et al. ANNALS OF HEMATOLOGY
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
- (2021) Philippe Moreau et al. LANCET ONCOLOGY
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A clinical perspective on plasma cell leukemia; current status and future directions
- (2021) Sherilyn A. Tuazon et al. Blood Cancer Journal
- Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS)
- (2021) Cyrille Touzeau et al. ANNALS OF HEMATOLOGY
- Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
- (2021) Faith Davies et al. ANNALS OF HEMATOLOGY
- Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
- (2021) Laura Rosiñol et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma
- (2021) Ghulam Rehman Mohyuddin et al. Clinical Lymphoma Myeloma & Leukemia
- Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
- (2021) Sara Bringhen et al. LEUKEMIA RESEARCH
- A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
- (2021) Joseph Mikhael et al. Blood Cancer Journal
- Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
- (2021) Cirino Botta et al. Frontiers in Oncology
- Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
- (2021) Hang Quach et al. BRITISH JOURNAL OF HAEMATOLOGY
- Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
- (2021) Simon J. Harrison et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
- (2021) Paul G. Richardson et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2021) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy.
- (2021) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
- (2021) Philippe Moreau et al. LANCET
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
- (2021) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma
- (2021) David Siegel et al. LEUKEMIA & LYMPHOMA
- CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
- (2021) Massimo Martino et al. Cancers
- Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma
- (2021) Thomas Martin et al. BLOOD
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
- (2021) Marcelo Capra et al. HAEMATOLOGICA
- Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
- (2021) Thierry Facon et al. LANCET ONCOLOGY
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
- (2021) Saad Z Usmani et al. LANCET ONCOLOGY
- Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond
- (2021) Boris Bozic et al. Cancers
- Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
- (2021) Arthur Bobin et al. Cancers
- Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
- (2021) Nicola Sgherza et al. Frontiers in Oncology
- ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS
- (2021) A Maiolino et al. Hematology Transfusion and Cell Therapy
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
- (2020) Nizar J. Bahlis et al. LEUKEMIA
- Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).
- (2020) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
- (2020) Meletios A. Dimopoulos et al. LEUKEMIA
- Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
- (2020) Fredrik H. Schjesvold et al. HAEMATOLOGICA
- Successful management of hemodialysis-dependent refractory myeloma with modified daratumumab, bortezomib and dexamethasone regimen
- (2020) Shinichi Mizuno et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
- (2020) Meletios Dimopoulos et al. LANCET
- Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
- (2020) Meletios A. Dimopoulos et al. Blood Cancer Journal
- Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
- (2020) Gils Roex et al. Journal of Hematology & Oncology
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
- (2019) Suzanne Trudel et al. Blood Cancer Journal
- Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
- (2019) Philippe Moreau et al. Blood Cancer Journal
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients
- (2019) Ajay K. Nooka et al. CANCER
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis
- (2019) Stefan Knop et al. LEUKEMIA
- Relapsed refractory multiple myeloma: a comprehensive overview
- (2019) Abdul Hamid Bazarbachi et al. LEUKEMIA
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma
- (2019) Michael Sebag et al. BLOOD
- Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
- (2019) David S. Siegel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study
- (2019) Saad Usmani et al. Clinical Lymphoma Myeloma & Leukemia
- Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
- (2019) Maria-Victoria Mateos et al. Clinical Lymphoma Myeloma & Leukemia
- Extramedullary multiple myeloma
- (2019) Manisha Bhutani et al. LEUKEMIA
- Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
- (2019) Philippe Moreau et al. Future Oncology
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
- (2018) Sara Bringhen et al. LEUKEMIA
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
- (2018) Meletios A. Dimopoulos et al. CANCER
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
- (2018) Andrew Spencer et al. HAEMATOLOGICA
- Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
- (2018) Laurent Garderet et al. BLOOD
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma
- (2018) Praful Ravi et al. Blood Cancer Journal
- Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
- (2017) N J Bahlis et al. LEUKEMIA
- Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series
- (2016) Joshua Richter et al. HEMATOLOGICAL ONCOLOGY
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
- (2016) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)
- (2016) Philippe Moreau et al. LEUKEMIA & LYMPHOMA
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
- (2015) J. J. Shah et al. BLOOD
- PACE as salvage therapy for relapsed or refractory multiple myeloma
- (2015) I. Isola et al. Clinical Lymphoma Myeloma & Leukemia
- Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
- (2015) Katja Weisel et al. Clinical Lymphoma Myeloma & Leukemia
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- The lymphoma-like polychemotherapy regimen “Dexa-BEAM” in advanced and extramedullary multiple myeloma
- (2014) Leo Rasche et al. ANNALS OF HEMATOLOGY
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- DCEP for relapsed or refractory multiple myeloma after therapy with novel agents
- (2013) Silvia Park et al. ANNALS OF HEMATOLOGY
- Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
- (2013) H. Ludwig et al. BLOOD
- Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy and the activity of pomalidomide on extramedullary myeloma
- (2011) K Detweiler Short et al. LEUKEMIA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started